[HTML][HTML] The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases

HU Kim, R Alten, L Avedano, A Dignass, F Gomollón… - Drugs, 2020 - Springer
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.

H Kim, R Alten, L Avedano, A Dignass, F Gomollón… - Drugs, 2020 - europepmc.org
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

[PDF][PDF] The Future of Biosimilars: Maximizing Benefits Across Immune‑Mediated Inflammatory Diseases

HU Kim, R Alten, L Avedano, A Dignass, F Gomollón… - Drugs, 2020 - lirias.kuleuven.be
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

[引用][C] The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

H Kim, R Alten, L Avedano, A Dignass, F Gomollon… - DRUGS, 2020 - iris.hunimed.eu
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory
Diseases IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste IT Italiano …

The Future of Biosimilars: Maximizing Benefits Across Immune‑Mediated Inflammatory Diseases

H Kim, R Alten, L Avedano, A Dignass, F Gomollón… - Drugs, 2020 - search.proquest.com
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic …

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.

HU Kim, R Alten, L Avedano, A Dignass, F Gomollón… - Drugs, 2020 - search.ebscohost.com
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

[HTML][HTML] The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

HU Kim, R Alten, L Avedano, A Dignass, F Gomollón… - Drugs, 2020 - ncbi.nlm.nih.gov
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

HU Kim, R Alten, L Avedano, A Dignass, F Gomollón… - Drugs, 2020 - duo.uio.no
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

HU Kim, R Alten, L Avedano, A Dignass… - …, 2020 - pubmed.ncbi.nlm.nih.gov
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic …

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

HU Kim, R Alten, L Avedano, A Dignass… - DRUGS, 2020 - scholarworks.bwise.kr
Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic …